Details

Autor(en) / Beteiligte

• von Hofsten, Joanna
• Johnsson Forsberg, Marianne
• Zetterberg, Madeleine

Titel

Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib

Ist Teil von

• The New England journal of medicine, 2016-01, Vol.374 (3), p.296-297

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• The Janus kinase 2 inhibitor ruxolitinib can produce defects in host defenses that may lead to opportunistic infections such as cytomegalovirus retinitis. To the Editor: A 67-year-old man received a diagnosis of primary myelofibrosis with extramedullary hematopoiesis and splenomegaly in 2009. In December 2013, treatment with ruxolitinib (Jakafi) was initiated at a dose of 15 mg twice daily. There was a palpable reduction in spleen size. In June 2014, the patient presented to his ophthalmologist with unilateral anterior uveitis. Treatment was initiated with mydriatic eyedrops and a low-dose regimen of topical glucocorticoids. During follow-up, no response to this therapy was noted, and signs of posterior involvement had developed. The patient was referred to our clinic, where a slight vitritis and a few . . .